erythromycin

erythromycin is a lipid of Polyketides (PK) class. Erythromycin is associated with abnormalities such as Systemic Inflammatory Response Syndrome, Pneumonia, Infection, Pneumococcal Infections and Exanthema. The involved functions are known as Pharmacodynamics, Sterility, Agent, Drug Kinetics and Adjudication. Erythromycin often locates in Blood, peritoneal, Extracellular, Ribosomes and apicoplast. The associated genes with erythromycin are P4HTM gene, SLC33A1 gene, FAM3B gene, Operon and Homologous Gene. The related lipids are Hydroxytestosterones, Steroids, Propionate, Mycolic Acids and campesterol. The related experimental models are Mouse Model and Knock-out.

References related to abnormalities published in J. Antimicrob. Chemother.

PMID	Journal	Published Date	Author	Title
10382903	J. Antimicrob. Chemother.	1999	Tzelepi E et al.	Erythromycin resistance amongst group A beta-haemolytic streptococci isolated in a paediatric hospital in Athens, Greece.
11815590	J. Antimicrob. Chemother.	2002	Vorbach H et al.	Endothelial cell compatibility of azithromycin and erythromycin.
11328768	J. Antimicrob. Chemother.	2001	Martin SJ et al.	The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae.
11328778	J. Antimicrob. Chemother.	2001	Zarantonelli L et al.	Decreased susceptibility to azithromycin and erythromycin mediated by a novel mtr(R) promoter mutation in Neisseria gonorrhoeae.
12003984	J. Antimicrob. Chemother.	2002	Jung R et al.	Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila.
12917252	J. Antimicrob. Chemother.	2003	Walsh F et al.	High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.
15243030	J. Antimicrob. Chemother.	2004	Peric M et al.	Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S.
14729765	J. Antimicrob. Chemother.	2004	Ortega E et al.	Modification of phagocytosis and cytokine production in peritoneal and splenic murine cells by erythromycin A, azithromycin and josamycin.
19864333	J. Antimicrob. Chemother.	2010	Glass SK et al.	Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006).
17449884	J. Antimicrob. Chemother.	2007	Docherty JJ et al.	Resveratrol inhibition of Propionibacterium acnes.
15772147	J. Antimicrob. Chemother.	2005	Halpern MT et al.	Meta-analysis of bacterial resistance to macrolides.
15590715	J. Antimicrob. Chemother.	2005	Amsden GW	Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
15590717	J. Antimicrob. Chemother.	2005	Marra F et al.	Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia.
15531597	J. Antimicrob. Chemother.	2004	Dias R and Caniça M	Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14.
16040621	J. Antimicrob. Chemother.	2005	Lee WK and Young BW	Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
16055509	J. Antimicrob. Chemother.	2005	Mamelli L et al.	Molecular basis of macrolide resistance in Campylobacter: role of efflux pumps and target mutations.
16162665	J. Antimicrob. Chemother.	2005	Rouquette-Loughlin CE et al.	Characterization of the MacA-MacB efflux system in Neisseria gonorrhoeae.
23169894	J. Antimicrob. Chemother.	2013	Metzler K et al.	Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.